A well-rounded life science company, OakLabs' singular goal is to support scientific companies and institutions with groundbreaking revelations, perhaps most notably in the realm of drug development, companion diagnostics (CDx) and development of IEC 62304 compliant medical device software.

The skilled team of quantum physicists and biochemists at OakLabs have revitalized the process of drug development with a new and efficient approach to patient selection in clinical trials. Their groundbreaking technique entails the use of an innovative algorithm to develop complex biomarker signatures which can accurately predict (non-)responders for specific drugs with superior accuracy. Not only does this lead to success in clinical trials, it can also help to gain market shares in a competitive environment, offering tangible results for continued market success after approval.


Dr. Jim Kallarackal

Frau Dr. Martina Schad

Press releases

The OakLabs GmbH receives High-Tech Gründerfonds seed funding for intelligent breeding methods

The development of new types of plants can be reduced by up to ten years with the reliable diagnostic DNA markers from OakLabs. With its seed investment, High-Tech Gründerfonds enables this young company to further develop its technology and to introduce it into the market. The primary objective of plant breeding is…

Info & Contact

Dr. Martina Schad
+49 33 02 / 2 07 13 91


Neuendorfstraße 16 b
16761 Hennigsdorf

In portfolio

28. Dec 2011